Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. more
Time Frame | SGMO | Sector | S&P500 |
---|---|---|---|
1-Week Return | -9.64% | -0.94% | -2.6% |
1-Month Return | 23.2% | -5.08% | -1.08% |
3-Month Return | 161.2% | -10.62% | 3.45% |
6-Month Return | 408.73% | -6.18% | 8.57% |
1-Year Return | 402.52% | 1.98% | 24.3% |
3-Year Return | -72.14% | -0.93% | 25.58% |
5-Year Return | -73.3% | 33.84% | 84.07% |
10-Year Return | -83% | 102.52% | 185.12% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 102.43M | 118.19M | 110.70M | 111.30M | 176.23M | [{"date":"2019-12-31","value":58.12,"profit":true},{"date":"2020-12-31","value":67.07,"profit":true},{"date":"2021-12-31","value":62.82,"profit":true},{"date":"2022-12-31","value":63.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 145.92M | 180.65M | 9.44M | 12.11M | 221.56M | [{"date":"2019-12-31","value":65.86,"profit":true},{"date":"2020-12-31","value":81.54,"profit":true},{"date":"2021-12-31","value":4.26,"profit":true},{"date":"2022-12-31","value":5.46,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 102.43M | 118.19M | 110.70M | 111.30M | (45.33M) | [{"date":"2019-12-31","value":86.66,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":93.66,"profit":true},{"date":"2022-12-31","value":94.17,"profit":true},{"date":"2023-12-31","value":-38.35,"profit":false}] |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | (25.72%) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-25.72,"profit":false}] |
Operating Expenses | 207.61M | 247.74M | 294.04M | 312.58M | 450.24M | [{"date":"2019-12-31","value":46.11,"profit":true},{"date":"2020-12-31","value":55.03,"profit":true},{"date":"2021-12-31","value":65.31,"profit":true},{"date":"2022-12-31","value":69.43,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (105.18M) | (129.55M) | (183.34M) | (201.28M) | (274.00M) | [{"date":"2019-12-31","value":-10518000000,"profit":false},{"date":"2020-12-31","value":-12955200000,"profit":false},{"date":"2021-12-31","value":-18333700000,"profit":false},{"date":"2022-12-31","value":-20128100000,"profit":false},{"date":"2023-12-31","value":-27400500000,"profit":false}] |
Total Non-Operating Income/Expense | 19.52M | 17.55M | 10.69M | 18.86M | 24.39M | [{"date":"2019-12-31","value":80.04,"profit":true},{"date":"2020-12-31","value":71.96,"profit":true},{"date":"2021-12-31","value":43.84,"profit":true},{"date":"2022-12-31","value":77.34,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (95.42M) | (120.78M) | (177.99M) | (191.85M) | (262.90M) | [{"date":"2019-12-31","value":-9541900000,"profit":false},{"date":"2020-12-31","value":-12077700000,"profit":false},{"date":"2021-12-31","value":-17799100000,"profit":false},{"date":"2022-12-31","value":-19184900000,"profit":false},{"date":"2023-12-31","value":-26290300000,"profit":false}] |
Income Taxes | (19.60M) | 345.00K | 306.00K | 429.00K | (5.07M) | [{"date":"2019-12-31","value":-4569,"profit":false},{"date":"2020-12-31","value":80.42,"profit":true},{"date":"2021-12-31","value":71.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1182.28,"profit":false}] |
Income After Taxes | (75.82M) | (121.12M) | (178.30M) | (192.28M) | (257.83M) | [{"date":"2019-12-31","value":-7581800000,"profit":false},{"date":"2020-12-31","value":-12112200000,"profit":false},{"date":"2021-12-31","value":-17829700000,"profit":false},{"date":"2022-12-31","value":-19227800000,"profit":false},{"date":"2023-12-31","value":-25783100000,"profit":false}] |
Income From Continuous Operations | (95.42M) | (121.12M) | (178.30M) | (192.28M) | (249.51M) | [{"date":"2019-12-31","value":-9541900000,"profit":false},{"date":"2020-12-31","value":-12112200000,"profit":false},{"date":"2021-12-31","value":-17829700000,"profit":false},{"date":"2022-12-31","value":-19227800000,"profit":false},{"date":"2023-12-31","value":-24950900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (75.82M) | (121.12M) | (178.30M) | (192.28M) | (257.83M) | [{"date":"2019-12-31","value":-7581800000,"profit":false},{"date":"2020-12-31","value":-12112200000,"profit":false},{"date":"2021-12-31","value":-17829700000,"profit":false},{"date":"2022-12-31","value":-19227800000,"profit":false},{"date":"2023-12-31","value":-25783100000,"profit":false}] |
EPS (Diluted) | (0.84) | (0.93) | (1.24) | (1.25) | (1.47) | [{"date":"2019-12-31","value":-84,"profit":false},{"date":"2020-12-31","value":-93,"profit":false},{"date":"2021-12-31","value":-124,"profit":false},{"date":"2022-12-31","value":-125,"profit":false},{"date":"2023-12-31","value":-147,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
SGMO | |
---|---|
Cash Ratio | 0.91 |
Current Ratio | 1.35 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
SGMO | |
---|---|
ROA (LTM) | -58.29% |
ROE (LTM) | -194.05% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
SGMO | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.65 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.35 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
SGMO | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 9.86 |
P/B | 12.32 |
Price/FCF | 48 |
EV/R | 9.00 |
EV/Ebitda | NM |
PEG | NM |
Sangamo Therapeutics Inc (SGMO) share price today is $2.39
Yes, Indians can buy shares of Sangamo Therapeutics Inc (SGMO) on Vested. To buy Sangamo Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SGMO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Sangamo Therapeutics Inc (SGMO) via the Vested app. You can start investing in Sangamo Therapeutics Inc (SGMO) with a minimum investment of $1.
You can invest in shares of Sangamo Therapeutics Inc (SGMO) via Vested in three simple steps:
The 52-week high price of Sangamo Therapeutics Inc (SGMO) is $3.18. The 52-week low price of Sangamo Therapeutics Inc (SGMO) is $0.3.
The price-to-earnings (P/E) ratio of Sangamo Therapeutics Inc (SGMO) is
The price-to-book (P/B) ratio of Sangamo Therapeutics Inc (SGMO) is 12.32
The dividend yield of Sangamo Therapeutics Inc (SGMO) is 0.00%
The market capitalization of Sangamo Therapeutics Inc (SGMO) is $563.24M
The stock symbol (or ticker) of Sangamo Therapeutics Inc is SGMO